Genetic polymorphisms in the cytokine genes and risk of hepatocellular carcinoma in low-risk non-Asians of USA

Carcinogenesis

Volumn 30, Issue 5, 2009, Pages 758-762

  Ognjanovic, Simona ^a,b   Yuan, Jian Min ^b   Chaptman, Ann K ^a   Fan, Yunhua ^b   Yu, Mimi C ^b  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CANCER RISK; CASE CONTROL STUDY; CHINESE; CONTROLLED STUDY; FEMALE; GENOTYPE; HUMAN; LABORATORY TEST; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TH1 CELL; TH2 CELL; UNITED STATES;

AFRICAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, HEPATOCELLULAR; CONTINENTAL POPULATION GROUPS; CYTOKINES; DIABETES COMPLICATIONS; DIABETES MELLITUS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC VARIATION; GENOTYPE; HUMANS; INFLAMMATION; INTERFERON-GAMMA; INTERLEUKINS; LIVER NEOPLASMS; LOS ANGELES; MALE; POLYMORPHISM, GENETIC; REGRESSION ANALYSIS; RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA; UNITED STATES;

EID: 65549130170     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgn286     Document Type: Article

References (41)

1. Parkin,D.M. et al. (2002) Cancer Incidence in Five Continents IARC, Lyon.
2. Llovet,J.M. et al. (2003) Hepatocellular carcinoma. Lancet, 362, 1907-1917.
3. Kim,W.R. et al. (2002) Burden of liver disease in the United States: Summary of a workshop. Hepatology, 36, 227-242.
4. Beasley,R.P. et al. (1981) Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. Lancet, 2 1129-1133.
5. Blumberg,B.S. et al. (1985) Hepatitis B virus and the prevention of primary cancer of the liver. J. Natl Cancer Inst., 74, 267-273.
6. Yeh,F.S. et al. (1989) Hepatitis B virus, aflatoxins, and hepatocellular carcinoma in southern Guangxi, China. Cancer Res., 49, 2506-2509.
7. Yu,M.C. et al. (2000) Epidemiology of hepatocellular carcinoma. Can. J. Gastroenterol., 14, 703-709.
8. Yu,M.C. et al. (1990) Prevalence of hepatitis B and C viral markers in black and white patients with hepatocellular carcinoma in the United States. J. Natl Cancer Inst., 82, 1038-1041.
9. Hassan,M.M. et al. (2002) Risk factors for hepatocellular carcinoma: Synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology, 36, 1206-1213.
10. Wideroff,L. et al. (1997) Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. J. Natl Cancer Inst., 89, 1360-1365.
11. Yu,M.C. et al. (1991) Nonviral risk factors for hepatocellular carcinoma in a low-risk population, the non-Asians of Los Angeles County, California. J. Natl Cancer Inst., 83, 1820-1826.
12. Yuan,J.M. et al. (2004) Synergism of alcohol, diabetes, and viral hepatitis on the risk of hepatocellular carcinoma in blacks and whites in the U.S. Cancer, 101, 1009-1017.
13. Chisari,F.V. (2000) Rous-Whipple Award Lecture. Viruses, immunity, and cancer: Lessons from hepatitis B. Am. J. Pathol., 156, 1117-1132.
14. Ferrari,C. et al. (2003) Immunopathogenesis of hepatitis B. J. Hepatol., 39 (suppl. 1), S36-S42.
15. Visvanathan,K. et al. (2006) Immunopathogenesis: Role of innate and adaptive immune responses. Semin. Liver Dis., 26, 104-115.
16. Lupberger,J. et al. (2007) Hepatitis B virus-induced oncogenesis. World J. Gastroenterol., 13, 74-81.
17. Paul,W.E. et al. (1994) Lymphocyte responses and cytokines. Cell, 76, 241-251.
18. Trinchieri,G. (1995) Interleukin-12: A proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu. Rev. Immunol., 13, 251-276.
19. Chung,R.T. (2005) Cytokine polymorphisms and hepatocellular carcinoma: to B or not to B. Cancer, 103, 654-656.
20. Nieters,A. et al. (2005) Effect of cytokine genotypes on the hepatitis B virus-hepatocellular carcinoma association. Cancer, 103, 740-748.
21. Yuan,J.M. et al. (2007) Genetic polymorphisms in the methylenetetrahydrofolate reductase and thymidylate synthase genes and risk of hepatocellular carcinoma. Hepatology, 46, 749-758.
22. Klein,C. et al. (2005) The IL-6-gp130-STAT3 pathway in hepatocytes triggers liver protection in T cell-mediated liver injury. J. Clin. Invest., 115, 860-869.
23. Mizuhara,H. et al. (1994) T cell activation-associated hepatic injury: Mediation by tumor necrosis factors and protection by interleukin 6. J. Exp. Med., 179, 1529-1537.
24. Kovalovich,K. et al. (2001) Interleukin-6 protects against Fas-mediated death by establishing a critical level of anti-apoptotic hepatic proteins FLIP, Bcl-2, and Bcl-xL. J. Biol. Chem., 276 26605-26613.
25. Hong,F. et al. (2002) Elevated interleukin-6 during ethanol consumption acts as a potential endogenous protective cytokine against ethanol-induced apoptosis in the liver: Involvement of induction of Bcl-2 and Bcl-x(L) proteins. Oncogene, 21, 32-43.
26. El-Zayadi,A.R. (2006) Heavy smoking and liver. World J. Gastroenterol., 12, 6098-6101.
27. Migita,K. et al. (2005) Cytokine gene polymorphisms in Japanese patients with hepatitis B virus infection - association between TGF-beta1 polymorphisms and hepatocellular carcinoma. J. Hepatol., 42, 505-510.
28. Park,B.L. et al. (2003) Association between interleukin 6 promoter variants and chronic hepatitis B progression. Exp. Mol. Med., 35, 76-82.
29. Haddy,N. et al. (2005) Biological variations, genetic polymorphisms and familial resemblance of TNF-alpha and IL-6 concentrations: STANISLAS cohort. Eur. J. Hum. Genet., 13, 109-117.
30. Huang,Y. et al. (2007) A functional SNP of interferon-gamma gene is important for interferon-alpha-induced and spontaneous recovery from hepatitis C virus infection. Proc. Natl Acad. Sci. USA, 104, 985-990.
31. Turner,D.M. et al. (1997) An investigation of polymorphism in the interleukin-10 gene promoter. Eur. J. Immunogenet., 24, 1-8.
32. Shin,H.D. et al. (2003) Interleukin 10 haplotype associated with increased risk of hepatocellular carcinoma. Hum. Mol. Genet., 12, 901-906.
33. Ben-Ari,Z. et al. (2003) Cytokine gene polymorphisms in patients infected with hepatitis B virus. Am. J. Gastroenterol., 98, 144-150.
34. Heneghan,M.A. et al. (2003) Frequency and nature of cytokine gene polymorphisms in hepatocellular carcinoma in Hong Kong Chinese. Int. J. Gastrointest. Cancer, 34, 19-26.
35. Yuan,J.M. et al. (1996) Low prevalence of hepatitis C infection in hepatocellular carcinoma (HCC) cases and population controls in Guangxi, a hyperendemic region for HCC in the People's Republic of China. Br. J. Cancer, 74, 491-493.
36. Yu,M.C. et al. (2004) Environmental factors and risk for hepatocellular carcinoma. Gastroenterology, 127, S72-S78.
37. Nair,M.P. et al. (2002) The flavonoid, quercetin, differentially regulates Th-1 (IFNgamma) and Th-2 (IL4) cytokine gene expression by normal peripheral blood mononuclear cells. Biochim. Biophys. Acta, 1593, 29-36.
38. Musik,I. et al. (1999) Immunomodulatory effect of selenosemicarbazides and selenium inorganic compounds, distribution in organs after selenium supplementation. Biometals, 12, 369-374.
39. Toma,S. et al. (1995) Effectiveness of beta-carotene in cancer chemoprevention. Eur. J. Cancer Prev., 4, 213-224.
40. Yuan,J.M. et al. (2006) Prediagnostic level of serum retinol in relation to reduced risk of hepatocellular carcinoma. J. Natl Cancer Inst., 98, 482-490.
41. Bondy,G.S. et al. (2000) Immunomodulation by fungal toxins. J. Toxicol. Environ. Health B Crit. Rev., 3, 109-143.